Form 4: SpringWorks Therapeutics Chief Accounting Officer Reports Stock Transactions

Michael Nofi, Chief Accounting Officer at SpringWorks Therapeutics, reported the withholding of shares to cover tax obligations related to vesting restricted stock units.

Summary

• Michael Nofi, the Chief Accounting Officer of SpringWorks Therapeutics, has filed a Form 4 detailing recent transactions involving the company's stock.
• The transactions involved the withholding of shares by the issuer to cover tax obligations related to the vesting of restricted stock units.
• These transactions are not sales by Mr. Nofi but rather a standard procedure for covering taxes on vested equity.
• On January 4, 2025, 2,388 shares were withheld at a price of $38.19 per share.
• On January 5, 2025, 1,636 shares were withheld at a price of $38.19 per share.
• On January 6, 2025, 1,009 shares were withheld at a price of $38.86 per share.
• Following these transactions, Mr. Nofi beneficially owns 23,694 shares of SpringWorks Therapeutics stock.

Sentiment

Score: 7

Explanation: The document reflects routine transactions related to executive compensation and tax obligations, which is neutral to slightly positive as it indicates the vesting of equity.

Industry Context

Form 4 filings are a standard part of regulatory compliance for company insiders and are common across all publicly traded companies.

Comparison to Industry Standards

• The transactions are typical for executives receiving stock-based compensation.
• The withholding of shares for tax obligations is a standard practice across publicly traded companies.
• The share prices at which the transactions occurred are within the normal range for the company's stock.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are related to tax obligations and not a sale of shares by the executive.

Key Dates

Keywords

Form 4, SpringWorks Therapeutics, SWTX, Michael Nofi, Chief Accounting Officer, stock transactions, restricted stock units, tax withholding